Company news
Rein Therapeutics, Inc. news in 2025
Rein Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
November 6, 2025
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
November 3, 2025
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
October 9, 2025
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
September 17, 2025
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
August 19, 2025
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
August 14, 2025
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing
July 30, 2025
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
June 24, 2025
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
May 27, 2025
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
May 19, 2025
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
May 12, 2025
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
May 1, 2025
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025
April 30, 2025
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
April 28, 2025
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
April 23, 2025
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
April 15, 2025
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
April 7, 2025
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
January 9, 2025